- Home
- NKSH vs GALT Comparison
NKSH vs GALT Comparison
Compare NKSH & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- GALT
- Stock Information
- Founded
- NKSH 1891
- GALT 2000
- Country
- NKSH United States
- GALT United States
- Employees
- NKSH N/A
- GALT N/A
- Industry
- NKSH Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- GALT Health Care
- Exchange
- NKSH Nasdaq
- GALT Nasdaq
- Market Cap
- NKSH 199.9M
- GALT 232.3M
- IPO Year
- NKSH N/A
- GALT N/A
- Fundamental
- Price
- NKSH $29.20
- GALT $4.74
- Analyst Decision
- NKSH Strong Buy
- GALT Strong Buy
- Analyst Count
- NKSH 1
- GALT 3
- Target Price
- NKSH $38.00
- GALT $6.00
- AVG Volume (30 Days)
- NKSH 8.0K
- GALT 371.9K
- Earning Date
- NKSH 10-23-2025
- GALT 11-12-2025
- Dividend Yield
- NKSH 5.21%
- GALT N/A
- EPS Growth
- NKSH 15.57
- GALT N/A
- EPS
- NKSH 1.77
- GALT N/A
- Revenue
- NKSH $49,801,000.00
- GALT N/A
- Revenue This Year
- NKSH $2.95
- GALT N/A
- Revenue Next Year
- NKSH $9.97
- GALT N/A
- P/E Ratio
- NKSH $16.35
- GALT N/A
- Revenue Growth
- NKSH 16.22
- GALT N/A
- 52 Week Low
- NKSH $23.75
- GALT $0.73
- 52 Week High
- NKSH $32.89
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- NKSH N/A
- GALT 63.90
- Support Level
- NKSH N/A
- GALT $4.10
- Resistance Level
- NKSH N/A
- GALT $5.06
- Average True Range (ATR)
- NKSH 0.00
- GALT 0.28
- MACD
- NKSH 0.00
- GALT -0.02
- Stochastic Oscillator
- NKSH 0.00
- GALT 72.92
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.